Q2 2024 Ginkgo Bioworks Holdings Inc Earnings Call Transcript
Key Points
- Ginkgo Bioworks Holdings Inc (DNA) ended the quarter with $730 million in cash and no bank debt, providing a strong cash margin of safety.
- The company is on track to achieve $100 million in annualized cost savings by the end of 2024 through aggressive headcount and operational cost reductions.
- Ginkgo Bioworks Holdings Inc (DNA) has successfully increased the number of active cell engineering programs by 33% year over year, indicating solid growth across most verticals.
- The company is expanding its offerings by opening its bioengineering platform directly to customer scientists, which could drive future revenue growth.
- Ginkgo Bioworks Holdings Inc (DNA) reaffirmed its 2024 revenue guidance, indicating confidence in its ability to execute despite restructuring efforts.
- Cell engineering revenue decreased by 20% compared to the second quarter of 2023, primarily due to a decline in revenue from early-stage customers.
- The company reported an adjusted EBITDA of negative $99 million, down from negative $80 million in Q2 2023, driven by a decrease in total revenue.
- Ginkgo Bioworks Holdings Inc (DNA) is undergoing significant restructuring, including notifying approximately 450 employees of job impacts, which could affect morale and operational stability.
- R&D expenses increased due to higher rent and AI-related spending, which may pressure margins if not offset by revenue growth.
- The company faces competitive challenges in the high-throughput functional genomics and antibody development space, where other players have established a presence.
Good evening. I'm Megan LeDuc, Manager of Investor Relations at Ginkgo Bioworks. I'm joined by Jason Kelly, our Co-Founder and CEO; and Mark Dmytruk, our CFO. Thanks as always for joining us. We're looking forward to updating you on our progress.
As a reminder, during the presentation today, we will be making forward-looking statements, which involve risks and uncertainties. Please refer to our filings with the SEC to learn more about these risks and uncertainties.
Today, in addition to updating you on the quarter, we are going to provide updates on our path towards adjusted EBITDA breakeven, including a deeper dive on how we're executing against our cost reduction targets as well as what we're doing to drive revenue. As usual, we'll end with a Q&A session, and I'll take questions from analysts, investors and the public. You can submit those questions to us in advance via X at #GinkgoResults results or e-mail investors at ginkgobioworks.com.
All right. Over to you, Jason.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
